Targeted Protein Degradation (PROTACs): A Practical Guide to Strategies, Challenges, and Therapeutic Opportunities
Targeted protein degradation is reshaping the landscape of drug discovery by offering a fundamentally different way to control disease biology. Instead of blocking a protein’s activity with traditional inhibitors, degradation strategies remove the protein from the cell, opening therapeutic possibilities for targets previously considered “undruggable.”How targeted protein degradation works
Small molecules called degraders recruit an E3 ubiquitin ligase to a disease-causing protein, tagging it for destruction by the cell’s proteasome. Bifunctional degraders (often called PROTACs) tether a ligand for the target to a ligand for an E3 ligase via a chemical linker.
The ternary complex formation triggers ubiquitination and selective elimination of the target protein. This catalytic mechanism means lower dosing can sometimes achieve sustained knockdown compared with occupancy-driven inhibition.
Why drug discovery teams are excited
– Access to hard-to-drug targets: Degradation enables modulation of scaffolding and non-enzymatic proteins that lack conventional active sites.
– Enhanced potency and duration: Degraders can achieve prolonged protein suppression even after compound clearance, reducing dosing frequency.
– Overcoming resistance: By removing the protein entirely, degraders may bypass resistance mechanisms that thwart inhibitors.
– Selectivity tuning: Design of linkers and ligands can favor specific ternary complexes, allowing isoform- or context-selective degradation.
Key scientific challenges
Despite promise, targeted protein degradation brings unique hurdles that drug discovery teams must address:
– Cell permeability and pharmacokinetics: Bifunctional molecules can be large and polar, complicating oral bioavailability and tissue distribution.
– E3 ligase repertoire: Most degraders exploit a small set of E3 ligases; expanding the toolbox is critical for tissue specificity and targeting diverse proteins.
– Off-target degradation: Unwanted recruitment of the ligase to non-target proteins can cause toxicity; comprehensive proteome-wide profiling is necessary.
– Predicting ternary complex formation: Structural determinants of productive complex formation are complex and require advanced structural and biophysical characterization.
Enabling technologies and strategies
Rapid progress is driven by integrated approaches:
– Structure-guided design: Cryo-EM and X-ray crystallography are increasingly used to resolve ternary complexes and guide linker optimization.
– Proteomics and chemoproteomics: Mass spectrometry-based workflows reveal degradation profiles and off-target effects across the proteome.
– Fragment-based and covalent chemistry: These approaches can identify novel ligands for both targets and E3 ligases, expanding chemical space.
– In-cell assays: Quantitative degradation assays, live-cell imaging, and reporter systems accelerate optimization cycles.
Therapeutic opportunities
Degraders are being explored across oncology, neurodegeneration, and immunology. Oncology programs focus on drivers and resistance mediators; neurodegenerative strategies aim to clear toxic aggregates or pathogenic isoforms.
The potential to degrade transcription factors, scaffolding proteins, and other traditionally “undruggable” classes creates broad clinical interest.
Practical guidance for researchers
– Prioritize targets with strong biology and demonstrable disease linkage.
– Invest early in assays that measure degradation kinetics and downstream functional effects.
– Use orthogonal proteomic readouts to detect off-target degradation and collateral biology.
– Iterate on linker design and E3 ligase selection to balance potency, selectivity, and ADME properties.
Targeted protein degradation represents a paradigm shift in drug discovery, turning protein removal into a viable therapeutic strategy. Teams that combine structural insight, proteomic profiling, and medicinal chemistry stand best positioned to translate this innovative modality into safe, effective medicines.